Charles Ng
Charles Ng
UCLA, NYU, Weill Cornell Pathology
Verified email at nyp.org
Title
Cited by
Cited by
Year
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E)
PI Poulikakos, Y Persaud, M Janakiraman, X Kong, C Ng, G Moriceau, ...
Nature 480 (7377), 387-390, 2011
13832011
Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance
H Shi, G Moriceau, X Kong, MK Lee, H Lee, RC Koya, C Ng, T Chodon, ...
Nature communications 3 (1), 1-8, 2012
6742012
Focused specificity of intestinal TH 17 cells towards commensal bacterial antigens
Y Yang, MB Torchinsky, M Gobert, H Xiong, M Xu, JL Linehan, F Alonzo, ...
Nature 510 (7503), 152-156, 2014
3952014
Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway
M Atefi, E von Euw, N Attar, C Ng, C Chu, D Guo, R Nazarian, ...
PloS one 6 (12), e28973, 2011
2222011
BRAFL597 mutations in melanoma are associated with sensitivity to MEK inhibitors
KB Dahlman, J Xia, K Hutchinson, C Ng, D Hucks, P Jia, M Atefi, Z Su, ...
Cancer discovery 2 (9), 791-797, 2012
1952012
Polymer nanofiber‐embedded microchips for detection, isolation, and molecular analysis of single circulating melanoma cells
S Hou, L Zhao, Q Shen, J Yu, C Ng, X Kong, D Wu, M Song, X Shi, X Xu, ...
Angewandte Chemie 125 (12), 3463-3467, 2013
1942013
Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma
T Chodon, B Comin-Anduix, B Chmielowski, RC Koya, Z Wu, M Auerbach, ...
Clinical Cancer Research 20 (9), 2457-2465, 2014
1922014
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition
H Shi, A Hong, X Kong, RC Koya, C Song, G Moriceau, W Hugo, ...
Cancer discovery 4 (1), 69-79, 2014
1552014
Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy
C Ma, AF Cheung, T Chodon, RC Koya, Z Wu, C Ng, E Avramis, ...
Cancer discovery 3 (4), 418-429, 2013
1042013
Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations
F Niehr, E von Euw, N Attar, D Guo, D Matsunaga, H Sazegar, C Ng, ...
Journal of translational medicine 9 (1), 1-13, 2011
882011
Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines
E von Euw, M Atefi, N Attar, C Chu, S Zachariah, BL Burgess, S Mok, C Ng, ...
Molecular cancer 11 (1), 1-9, 2012
772012
Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
M Atefi, B Titz, E Avramis, C Ng, DJL Wong, A Lassen, M Cerniglia, ...
Molecular cancer 14 (1), 1-12, 2015
432015
COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors
H Escuin-Ordinas, M Atefi, Y Fu, A Cass, C Ng, RR Huang, S Yashar, ...
Molecular oncology 8 (2), 250-260, 2014
422014
Heritable gene regulation in the CD4: CD8 T cell lineage choice
PDA Issuree, CP Ng, DR Littman
Frontiers in immunology 8, 291, 2017
302017
Niche-selective inhibition of pathogenic Th17 cells by targeting metabolic redundancy
L Wu, KER Hollinshead, Y Hao, C Au, L Kroehling, C Ng, WY Lin, D Li, ...
Cell 182 (3), 641-654. e20, 2020
162020
The histone chaperone CAF-1 cooperates with the DNA methyltransferases to maintain Cd4 silencing in cytotoxic T cells
C Ng, M Aichinger, T Nguyen, C Au, T Najar, L Wu, KR Mesa, W Liao, ...
Genes & development 33 (11-12), 669-683, 2019
132019
Anthrax toxin receptor 1/tumor endothelial marker 8: mutation of conserved inserted domain residues overrides cytosolic control of protective antigen binding
JD Ramey, VA Villareal, C Ng, SC Ward, JP Xiong, RT Clubb, KA Bradley
Biochemistry 49 (34), 7403-7410, 2010
122010
CRAF R391W is a melanoma driver oncogene
M Atefi, B Titz, J Tsoi, E Avramis, A Le, C Ng, A Lomova, A Lassen, ...
Scientific reports 6 (1), 1-11, 2016
82016
Tcf1 and Lef1 pack their own HDAC
CP Ng, DR Littman
Nature immunology 17 (6), 615-616, 2016
42016
Melanomas with rare BRAF mutations and their responses to MAPK pathway blocking drugs.
MS Atefi, CP Ng, DJ Wong, L Robert, H Escuin-Ordinas, A Lassen, ...
Cancer Research 73 (8 Supplement), 915-915, 2013
12013
The system can't perform the operation now. Try again later.
Articles 1–20